Anti-GQ1b antibodies have been found in patients with Miller Fisher syndrome as well as its related conditions. Our aim was to identify the mechanism by which autoantibodies produce various clinical presentations in 'anti-GQ1b antibody syndrome'.
To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs).
Human Activity Recognition (HAR) has emerged as a critical research area due to its extensive applications in various real-world domains. Numerous CSI-based datasets have been established to support the development and evaluation of advanced HAR algorithms. However, existing CSI-based HAR datasets are frequently limited by a dearth of complexity and diversity in the activities represented, hindering the design of robust HAR models. These limitations typically manifest as a narrow focus on a limited range of activities or the exclusion of factors influencing real-world CSI measurements. Consequently, the scarcity of diverse training data can impede the development of efficient HAR systems. To address the limitations of existing datasets, this paper introduces a novel dataset that captures spatial diversity through multiple transceiver orientations over a high dimensional space encompassing a large number of subcarriers. The dataset incorporates a wider range of real-world factors including extensive activity range, a spectrum of human movements (encompassing both micro-and macro-movements), variations in body composition, and diverse environmental conditions (noise and interference). The experiment is performed in a controlled laboratory environment with dimensions of 5 m (width) × 8 m (length) × 3 m (height) to capture CSI measurements for various human activities. Four ESP32-S3-DevKitC-1 devices, configured as transceiver pairs with unique Media Access Control (MAC) addresses, collect CSI data according to the Wi-Fi IEEE 802.11n standard. Mounted on tripods at a height of 1.5 m, the transmitter devices (powered by external power banks) positioned at north and east send multiple Wi-Fi beacons to their respective receivers (connected to laptops via USB for data collection) located at south and west. To capture multi-perspective CSI data, all six participants sequentially performed designated activities while standing in the centre of the tripod arrangement for 5 s per sample. The system collected approximately 300-450 packets per sample for approximately 1200 samples per activity, capturing CSI information across the 166 subcarriers employed in the Wi-Fi IEEE 802.11n standard. By leveraging the richness of this dataset, HAR researchers can develop more robust and generalizable CSI-based HAR models. Compared to traditional HAR approaches, these CSI-based models hold the promise of significantly enhanced accuracy and robustness when deployed in real-world scenarios. This stems from their ability to capture the nuanced dynamics of human movement through the analysis of wireless channel characteristic from different spatial variations (utilizing two-diagonal ESP32 transceivers configuration) with higher degree of dimensionality (166 subcarriers).
To study the clinical profile of Guillain-Barré syndrome (GBS) patients who died in 4 Asian countries in order to understand factors underlying any variation in mortality.
The shortage of deceased donors led to an increase of living related renal transplant performed in the presence of donor-specific antibodies (DSAs) or ABO incompatibilities. There are various desensitization protocols that have been proposed. Here, we describe the outcome of these sensitized patients. This is a prospective cohort study recruiting all kidney transplant recipients from August 2016 until June 2018. Deceased donations, ABO incompatible patients, and sensitized patients who were not prescribed on our desensitization protocol were excluded. Recipients were screened for the presence of HLA-antibodies 1 month before transplant. Those with positive DSA will undergo flow cytometry (risk stratification). We are using a protocol that consisted of intravenous rituximab 200 mg (day -14), intravenous antithymocyte globulin 5mg/kg (day 0-4), plasma exchange post transplant for patients with mean fluorescent intensity (MFI) < 3000, and negative flow cytometry. Those patients with MFI ≥ 3000 or positive flow cytometry need extra cycles pretransplant. A total of 40 patients were recruited, and 20 were sensitized patients. Among the sensitized group 4 of 20 had flow cytometry crossmatch positive, while all had preformed HLA-DSA. A total of 8 of 20 had class I HLA-DSA, 11 of 20 had class II HLA-DSA, and 1of 20 was positive for both class I and II HLA-DSA. Mean immunodominant MFI was 2133.4 (standard deviation [SD], 4451.24) and 1383.7 (SD, 2979.02) for class I and class II, respectively. At 1 year, mean serum creatinine was 108.90 (SD, 25.95) and 118.42 (SD, 31.68) in sensitized and unsensitized patients, respectively. One of 20 unsensitized patients had Banff 1B rejection at 3 months, and there was no significant rejection in sensitized patients at 6 months and 1 year. There was no difference in the occurrence of de novo HLA-DSA between the groups. Desensitization protocols may help to overcome incompatibility barriers in living donor renal transplant. The combination of low-dose rituximab, antithymocyte globulin, and judicious use of plasma exchange has worked well for our cohort.